Vaxart Q3 2026 Earnings Date & Estimates

Vaxart (OTCMKTS:VXRT) is a biotechnology company focused on developing oral recombinant vaccines delivered in tablet form. Its proprietary platform is designed to stimulate immune responses at mucosal surfaces, such as those in the nose and mouth, in addition to generating systemic immunity. The company’s approach is intended to offer a needle-free alternative to traditional injectable vaccines.

Vaxart’s development programs have included oral vaccine candidates for coronavirus infections, norovirus and influenza. Its coronavirus research has focused on tablet-based vaccines designed to target respiratory viruses and potentially support protection at the site where infection begins. The company’s candidates remain subject to clinical development and regulatory review, and its products are not broadly marketed vaccines.

Headquartered in South San Francisco, California, Vaxart serves the global biopharmaceutical and vaccine markets through research, development and potential commercialization of oral vaccine products. The company became a publicly traded entity following the 2018 combination of Vaxart and Aviragen Therapeutics, after which the combined company adopted the Vaxart name and continued development of Vaxart’s oral vaccine platform.